Gilead CEO Daniel O’Day has hired Berger away from Sanofi. Elsewhere, Lonza is reorganizing and Bausch + Lomb is exploring a ...

US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief ...

Gilead Sciences names Sanofi's Dietmar Berger as new CMO, replacing Merdad Parsey amid challenging year marked by setbacks ...

Gilead Sciences, Inc. has announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, as Chief Medical ...

Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...

Gilead Sciences said on Thursday it has appointed Sanofi's Dietmar Berger as its chief medical officer, replacing incumbent ...

Most recently, Dr Berger was the Chief Medical Officer and Global Head of Development at Sanofi, where he led development ...

US private equity giant Bain Capital offered to buy Insignia Financial Ltd., the Australian financial services firm, in a ...

Gilead Sciences named former Sanofi executive Dietmar Berger as chief medical officer, effective Jan. 2, succeeding Merdad Parsey.

Gilead (GILD) announced that Dietmar Berger will join the company on January 2, 2025, as Chief Medical Officer and will become a member of ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Dietmar Berger, MD, PhD, will join the company on January 2, 2025, ...

The hematology market is experiencing significant growth driven by the increasing prevalence of blood-related disorders, advancements in research and product development, and the rising number of ...